Nerviano Medical Sciences disclosed data on novel molecules suitable for the generation of antibody drug conjugates at the meeting World ADC San Diego (USA), 26-29 October 2014.
Antibody drug conjugates (ADCs) represent a valuable approach to cancer therapy whereby antibodies are combined with potent cytotoxic compounds for selective tumor cell delivery and decreased toxicity.
Nerviano Medical Sciences reports on the identification and related proof of concept studies for a novel chemical series of minor groove binding alkylating agents (MGAAs) possessing physicochemical properties highly compatible with deployment as antibody payloads. Coupling of NMS-P45, a lead member of the series, to therapeutic monoclonal antibodies confirmed excellent suitability for production of homogeneous, non aggregated conjugates with highly potent and selective antitumor activity.
Presentation title: NMS-P945 a new drug-linker highly suited to generation of novel antibody drug conjugates (ADCs)
Authors: Valsasina, B et al.
Meeting: Word ADC San Diego, 26-29 October 2014 Link to the conference website: http://worldadc-usa.com/